Mechanisms of disease: hypertrophic cardiomyopathy
- PMID: 22027658
- DOI: 10.1038/nrcardio.2011.159
Mechanisms of disease: hypertrophic cardiomyopathy
Abstract
Hypertrophic cardiomyopathy (HCM) is the most-common monogenically inherited form of heart disease, characterized by thickening of the left ventricular wall, contractile dysfunction, and potentially fatal arrhythmias. HCM is also the most-common cause of sudden cardiac death in individuals younger than 35 years of age. Much progress has been made in the elucidation of the genetic basis of HCM, resulting in the identification of more than 900 individual mutations in over 20 genes. Interestingly, most of these genes encode sarcomeric proteins, such as myosin-7 (also known as cardiac muscle β-myosin heavy chain; MYH7), cardiac myosin-binding protein C (MYBPC3), and cardiac muscle troponin T (TNNT2). However, the molecular events that ultimately lead to the clinical phenotype of HCM are still unclear. We discuss several potential pathways, which include altered calcium cycling and sarcomeric calcium sensitivity, increased fibrosis, disturbed biomechanical stress sensing, and impaired cardiac energy homeostasis. An improved understanding of the pathological mechanisms involved will result in greater specificity and success of therapies for patients with HCM.
Similar articles
-
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. Clin Res Cardiol. 2018. PMID: 28840316 Review.
-
Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.Forensic Sci Int Genet. 2021 May;52:102478. doi: 10.1016/j.fsigen.2021.102478. Epub 2021 Feb 3. Forensic Sci Int Genet. 2021. PMID: 33588347
-
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.J Cardiovasc Med (Hagerstown). 2006 Aug;7(8):601-7. doi: 10.2459/01.JCM.0000237908.26377.d6. J Cardiovasc Med (Hagerstown). 2006. PMID: 16858239
-
Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy.Circ J. 2013;77(9):2358-65. doi: 10.1253/circj.cj-13-0294. Epub 2013 Jun 19. Circ J. 2013. PMID: 23782526 Clinical Trial.
-
Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes.Ann Med. 2004;36(1):23-32. doi: 10.1080/07853890310017161. Ann Med. 2004. PMID: 15000344 Review.
Cited by
-
Molecular modeling of disease causing mutations in domain C1 of cMyBP-C.PLoS One. 2013;8(3):e59206. doi: 10.1371/journal.pone.0059206. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527136 Free PMC article.
-
Loss of the AE3 Cl(-)/HCO(-) 3 exchanger in mice affects rate-dependent inotropy and stress-related AKT signaling in heart.Front Physiol. 2013 Dec 31;4:399. doi: 10.3389/fphys.2013.00399. eCollection 2013. Front Physiol. 2013. PMID: 24427143 Free PMC article.
-
Human-induced pluripotent stem cell models of inherited cardiomyopathies.Curr Opin Cardiol. 2014 May;29(3):214-9. doi: 10.1097/HCO.0000000000000049. Curr Opin Cardiol. 2014. PMID: 24576884 Free PMC article. Review.
-
Signalling in sarcomeres in development and disease.Neth Heart J. 2013 Jul;21(7-8):367-71. doi: 10.1007/s12471-013-0435-6. Neth Heart J. 2013. PMID: 23864481 Free PMC article.
-
Order-Disorder Transitions in the Cardiac Troponin Complex.J Mol Biol. 2016 Jul 31;428(15):2965-77. doi: 10.1016/j.jmb.2016.06.022. Epub 2016 Jul 6. J Mol Biol. 2016. PMID: 27395017 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous